Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop
March was a volatile month for the healthcare sector, again impacted by the macro-economic and political backdrop. While the sector ended March in negative territory, it held up somewhat better than many other sectors, protected both by its overall low valuation and by its defensive characteristics. The downward trend in the sector was led primarily […]
Monthly summary – February 2025: Sentiment turned sour in February
MONTHLY COMMENT After a strong start to the year for the healthcare sector, sentiment turned sour in February, which was characterized by political and macroeconomic uncertainties. Equity flows favored defensive stocks, with rotation benefiting the larger pharmaceutical companies, among others. Medtech and biotech were caught on the other side of said rotation while healthcare services […]
Rhenman & Partners strengthens its Operations Team
Rhenman & Partners hires Hampus Tober as Operations Manager. Hampus will have a central position within the organization and close collaborations across the firm. Hampus will report to the Rhenman & Partners’ COO, Mikael Olsson. He will focus on operational and administrative processes, with emphasis on risk and compliance. Hampus joins Rhenman & Partners from […]
Monthly comment – January 2025: All sectors except technology closing in positive territory
SUMMARY For the healthcare sector, the strong market in January was largely a reversal of the weak performance in December. US politics continued to shape the market as a whole, with ”Trump trades” gaining even more traction at the expense of other investment themes. In the healthcare sector, some of the high-level uncertainties in December […]
Monthly comment – December 2024
SUMMARY A challenging ending to a volatile year. December was the healthcare sector’s worst month of the year. The murder of Brian Thompson, CEO of UnitedHealthcare, shocked the sector to its core. Novo Nordisk released the much-anticipated phase III data for CagriSema which missed market expectations, and the stock fell sharply. At the eleventh hour, […]
Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications
Monthly comment November saw heightened volatility across financial markets, driven by the dramatic US election, Trump’s victory, his controversial cabinet nominations, fluctuating interest rates and currencies, geopolitical tensions as well as the earnings season. Donald Trump secured both the Electoral College and the popular vote. Republicans gained control of the Senate and the House of […]
October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes
Monthly comment – October 2024 During October, the focus was initially on the earnings season where financials performed well. However, the high degree of uncertainty surrounding the election in the US increasingly led to heightened market volatility, where both sectors and individual stocks were affected by the polls. There were significant differences in currencies as […]
Monthly summary – September 2024
As in the previous month, September began with a spike in volatility. Mixed economic data, interest rate uncertainties and geopolitical tensions, all added to a weak start. With the benefit of hindsight, after nine out of the past ten months ended in the green, some profit-taking was perhaps to be expected, particularly bearing in mind […]
Rhenman & Partners strengthens its Investor Relations team further
Rhenman & Partners hires Mattias Hagen as Investor Relations Director. Mattias joins Rhenman & Partners Investor Relations team based in Stockholm consisting of Erica von Bahr and Tom Josephson. In his role, Mattias will work both with Swedish and international investors. Most recently Mattias has worked with institutional investors at Carnegie Fonder. Prior to that […]